|
State of Israel
|
Not Applicable
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Waltham, Massachusetts 02451
(617) 859-6409
|
Gary Emmanuel, Esq.
Greenberg Traurig, P.A.
One Azrieli Center
Round Tower, 30th floor
132 Menachem Begin Rd
Tel Aviv 6701101
Tel: +972 (0) 3.636.6000
|
Sharon Rosen, Adv.
FISCHER (FBC & Co.)
146 Menachem Begin Street
Tel Aviv 6492103, Israel
Tel: +972 -3-6944111
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☐
|
|
|
|
Emerging growth company
|
☐
|
|
|
•
|
our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC
on March 31, 2025;
|
|
|
|
|
|
|
•
|
our Reports on Form 6-K filed with the SEC on March 31, 2025, May 23, 2025, May 27, 2025, May 30, 2025, June 30, 2025, August 14, 2025, September 29, 2025, November 17, 2025 and November 24, 2025 (in each
case, to the extent expressly incorporated by reference into our effective registration statements filed by us under the Securities Act); and
|
|
|
|
|
|
|
•
|
the description of our ordinary shares contained in Exhibit 2.2 to our Annual Report on Form
20-F for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or report filed with the SEC for the purpose of updating such description.
|
|
|
BioLineRx Ltd.
2 HaMa’ayan Street
Modi’in 7177871, Israel
Attention: Corporate Secretary
Tel.: +972-8-642-9100
e-mail: [email protected]
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
Method of Filing
|
|
|
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
|
|
Filed herewith.
|
|
|
BIOLINERX LTD.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
|
Philip A. Serlin
|
|
|
|
|
Chief Executive Officer
|
|
|
SIGNATURE
|
|
TITLE
|
|
DATE
|
|
|
|
|
|
|
|
/s/ Philip A. Serlin
|
|
Chief Executive Officer,
|
|
January 23, 2026
|
|
Philip A. Serlin
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Mali Zeevi
|
|
Chief Financial Officer
|
|
January 23, 2026
|
|
Mali Zeevi
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Aharon Schwartz
|
|
Chairman of the Board
|
|
January 23, 2026 |
|
Aharon Schwartz
|
|
|
|
|
|
|
|
|
|
|
|
/s/ B.J. Bormann
|
|
Director
|
|
January 23, 2026 |
|
B.J. Bormann
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Gal Cohen
|
|
Director
|
|
January 23, 2026 |
|
Gal Cohen
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Rami Dar
|
|
Director
|
|
January 23, 2026 |
|
Rami Dar
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Raphael Hofstein
|
|
Director
|
|
January 23, 2026 |
|
Raphael Hofstein
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Avraham Molcho
|
|
Director
|
|
January 23, 2026 |
|
Avraham Molcho
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Sandra Panem
|
|
Director
|
|
January 23, 2026 |
|
Sandra Panem
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Shaoyu Yan
|
|
Director
|
|
January 23, 2026 |
|
Shaoyu Yan
|
|
|
|
|
|
|
BioLineRx USA, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
|
Name: Philip A. Serlin
|
|
|
|
|
Title: Authorized Person
|
|